GlaxoSmithKline to publish trial data online
June 24, 2004GlaxoSmithKline has announced it is to make data from all of its trials available online in an effort to counter …
Contract research looks East
June 24, 2004Contract research organisations (CRO) have benefited from the pressure on the pharmaceutical industry to maintain a flow of blockbusters at …
Study finds dementia risk for HRT
June 24, 2004A new study has found that both oestrogen-only and oestrogen plus progestogen hormone replacement therapies may increase the risk of …
Positive opinion on Raptiva in Europe
June 24, 2004Raptiva, a new psoriasis treatment to be marketed by Serono in Europe has gained a positive opinion from the EMEA.The …
Exanta launched in first market
June 23, 2004AstraZeneca's new oral anticoagulant Exanta has been launched in Germany, its first global market.The drug is the first in a …
Are you structured for success?
June 18, 2004In a world of constant change, why have many pharma companies stuck to traditional organisational structures? Are they really the …
Schering restructures for long-term growth
June 17, 2004German pharmaceutical company Schering AG will no longer conduct research and development into cardiovascular or, with a few exceptions, central …
Cancer tsar sets out plan to end postcode prescribing
June 15, 2004The government has promised to eliminate persistent variations in access to cancer drugs across England and Wales, and has unveiled …
Pharmacists to take on public health role
June 15, 2004The government's drive to transform pharmacists into leading frontline healthcare professionals is to be spearheaded by a new consortium of …
Xenova’s cocaine vaccine shows promise
June 15, 2004Cocaine addicts could be helped by a vaccine currently in development by UK biotech company Xenova, phase II results from …
Abbott buys heart drug from Aventis for $300 million
June 10, 2004Chicago-based Abbott Laboratories has bought the marketing and manufacturing rights for cardiovascular drug trandolapril from Aventis, in a deal worth …
New schizophrenia drug Abilify gets European go-ahead
June 10, 2004Abilify, Bristol-Myers Squibb and Otsuka's antipsychotic has received European Union marketing approval and will be promoted for having fewer side …
Lipitor halves stroke risk in diabetes patients
June 8, 2004New Lipitor data suggests the drug cut the risk of stroke by half in diabetes patients, the compelling evidence potentially …
Shire relocates R&D headquarters to US
June 3, 2004Shire Pharmaceuticals has relocated its research and development headquarters to the US as the company looks to increase its penetration …
Oxford BioMedica one step closer to Holy Grail of nerve damage
June 3, 2004The promise of a gene-based technology which might one day cure spinal injuries and paralysis has moved one step closer …
Latest content
FibroFind appoints Lee Borthwick as CEO
